Publication Date
2015-01-15
End of Embargo
Supervisor
Rights
Peer-Reviewed
Yes
Open Access status
closedAccess
Accepted for publication
Institution
Department
Awarded
Embargo end date
Collections
Additional title
Abstract
The development of therapeutics to treat cancer is conceptually more difficult than for nonlife-threatening diseases for several reasons, including its complex pathophysiological nature, the molecular individuality of each tumor, and the robustness and predictability of preclinical models toward determining efficacy and safety. A major limitation to development of a “blockbuster” therapeutic strategy is the infinite combination of cellular and molecular perturbations and associated heterogeneity of causative genetic factors driving disease progression. Although challenging, the diversity of drug targets, coupled with the lethality of the disease, has encouraged studies of a vast array of approaches and opportunities for disease treatment over the years.
Version
No full-text in the repository
Citation
Gill JH and Shnyder S (2015) Oncology Activity. In: Hock FJ (Ed) Drug Discovery and Evaluation: Pharmacological Assay. Switzerland : Springer.
Link to publisher’s version
Link to published version
Link to Version of Record
Type
Book chapter